Skip to main content

Table 2 Individual values for tumor diffusivity and morphological tumor volumes at baseline and follow-up

From: 18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

Number

Groupa

ADCBaseline (mm2x10−3/s)

ADCFollow-up (mm2x10−3/s)

∆ADC (mm2x10−3/s)

VolumeBaseline (mm3)

VolumeFollow-up (mm3)

∆Volume (mm3)

1

T

0.84

0.84

0.00

163.0

166.3

3.3

2

T

0.88

1.16

0.28

25.7

33.5

7.8

3

T

0.74

0.72

−0.02

19.1

99.5

80.4

4

T

0.77

0.86

0.09

188.8

255.5

66.7

5

T

0.87

0.82

−0.05

88.5

281.1

192.6

6

T

0.62

0.84

0.22

154.9

107.7

−47.2

7

T

0.79

1.07

0.28

67.2

48.3

−18.9

8

T

0.71

0.87

0.16

38.7

50.8

12.1

9

T

0.66

0.83

0.17

232.5

264.1

31.6

10

T

0.73

0.81

0.08

62.0

123.0

61.0

11

T

0.76

1.07

0.31

48.9

31.9

−17.0

12

T

0.97

0.85

−0.12

45.6

107.9

62.3

Mean ± SDb

T

0.78 ± 0.10

0.90 ± 0.13

0.12 ± 0.14

94.6 ± 71.4

130.8 ± 91.3

36.2 ± 63.2

13

C

0.85

0.77

−0.08

119.0

356.0

237.0

14

C

0.70

0.63

−0.07

320.6

777.6

457.0

15

C

0.86

0.69

−0.17

103.1

379.7

276.6

16

C

0.96

0.76

−0.20

81.5

212.9

131.4

17

C

0.78

0.63

−0.15

138.0

371.4

233.4

18

C

0.73

0.61

−0.12

109.0

292.9

183.9

19

C

0.87

0.71

−0.16

72.7

301.7

229.0

20

C

0.61

0.61

0.00

232.7

541.0

308.3

21

C

0.79

0.69

−0.10

31.8

203.5

171.7

Mean ± SDb

C

0.79 ± 0.10

0.68 ± 0.06

−0.12 ± 0.06

134.3 ± 89.0

381.9 ± 179.4

247.6 ± 95.1

  1. aT = therapy group; C = control group
  2. bSD = standard deviation